Who We Are
Menacure Healthcaretraditional business model hinges on the ability to identify promising newmolecules and promote them with an extensive marketing and sales presence. In thepredominant version of this model, a single company may employ contractors to supplementits own efforts, but it seeks to generate profits on its own. In essence, it pursues what mightbe called a “profit alone” path.
But,now, the strategy of singlehandedly placing big bets on a few molecules, marketing themheavily and turning them into blockbusterswill not suffice. As J.P. Garnier, former chiefexecutive of GlaxoSmithKline, recently pointed out, it is a “business model where you areguaranteed to lose your entire book ofbusiness every 10 to 12 years”.More importantly still,it is a business modelthat will no longer meet the market’s needs. Management guru ClayChristensen has convincingly demonstrated how disruptive innovations in various industrieshave dismantled the prevailing business model, by enabling new players to target the leastprofitable customer segments and gradually move upstream until they can satisfy thedemands of every customer–at which point the old business model collapses.
Pharma is currently undergoing just such a period of disruptive innovation. Most medicineswill be paid for on the basis of the results they deliver–and since many factors influenceoutcomes, this means that it will have to move into the health management space, both topreserve the value of its products and to avoid beingside linedby new players. If it is to makeground breakingnew medicines for which governments and health insurers are prepared topay premium prices, it will also have to build the relationships and infrastructure required toensure that it can get access to the outcomes data they collect. In short, the rules of the gameare shifting dramatically. And, as Michael G. Jacobides, Associate Professor of Strategic andInternational Management at the London Business School, notes, when an entire “industryarchitecture” is transformed, it is not only “who does what” that changes, it is also “who takeswhat”.4 By 2020, no pharmaceutical company will be able to “profit alone”. It will, rather, haveto “profit together”, by joining forces with a wide range of organisations, from academicinstitutions, hospitals and technology providers to companies offering complianceprogrammes, nutritional advice, stress management, physiotherapy, exercise facilities, healthscreening and other such services.
Vision & Mission & Values
The expectations and needs toward healthcare are increasing due to the growth and aging of populations and dramatic advancements in science and technology. On the other hand, with limited resources and finances, realizing a healthy life for all people is a common global challenge. Our goal is to provide solutions that help solve social issues and lead to the advancement of society by taking advantage of our high level of science and technology to innovate. In addition to delivering innovative new drugs, we are broadening our contribution to patients through initiatives for providing drugs and healthcare services that transcend the boundaries of drugs. Going forward, we will deliver value with a broader view by innovating through collaboration with players in diverse industries, such as the IT and digital sector.
As the CEO of a pharmaceutical company, it is my responsibility to create accompany that is competitive, resilient and innovative, allowing us to successfully navigate in a complex and constantly changing environment.
Our leadership team is committed to provide efficient business strategies and local plans respecting the Middle East business environments and considering every possible internal competency that could lead to quick market access and efficient business operation. Our leadership team is enjoying robust experiences with proven records of success in the pharmaceutical business fields.
We are committed to improve patients’ life in the Middle East countries through introducing solutions for conditions with un-met medical needs, supporting the patients journey from diagnosis, starting therapy and maintaining his treatments through developing several partnering and patients support programs with different health and social communities.
Thank you for supporting our vision and together we will march towards fulfilling that goal.